Incremental lowering of low-density lipoprotein cholesterol with Ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy

Canadian Journal of Cardiology

Volumn 29, Issue 11, 2013, Pages 1395-1399

  Ziada, Ahmed ^a   Schwarz, Ute I ^a   DeGorter, Marianne K ^a   Tirona, Rommel G ^a   Ban, Matthew R ^a   Kim, Richard B ^a   Hegele, Robert A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; RETROSPECTIVE STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; ASPARTATE AMINOTRANSFERASES; AZETIDINES; CHOLESTEROL, LDL; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; GLUCURONIDES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84886854727     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.08.003     Document Type: Article

References (20)

1. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
2. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
3. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
4. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists' (CTT) Collaborators.
5. Altmann S.W., Davis H.R., Zhu L.J., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
6. Huff M.W., Pollex R.L., Hegele R.A. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006, 26:2433-2438.
7. Knopp R.H., Dujovne C.A., Le Beaut A., et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003, 57:363-368.
8. Bays H.E., Moore P.B., Drehobl M.A., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001, 23:1209-1230.
9. Mauro V.F., Tuckerman C.E. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother 2003, 37:839-848.
10. Schwarz UI. Intestinal and hepatic drug transporters and their role in the disposition of lipid-lowering drugs (doctoral thesis). Western Electronic Thesis and Dissertation Repository, 2012 (ETD No. 1970).
11. Robinson J.G. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 2008, 101:1009-1015.
12. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192. SHARP Investigators.
13. Cannon C.P., Giugliano R.P., Blazing M.A., et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-832. IMPROVE-IT Investigators.
14. Weston C. Place of ezetimibe in clinical practice. Hosp Med 2003, 64:473-478.
15. Dujovne C.A., Bays H., Davidson M.H., et al. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. JClin Pharmacol 2001, 41:70-78.
16. Kosoglou T., Statkevich P., Johnson-Levonas A.O., et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005, 44:467-494.
17. Ezzet F., Wexler D., Statkevich P., et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. JClin Pharmacol 2001, 41:943-949.
18. Chan J., Kushwaha R.S., Vandeberg J.F., Vandeberg J.L. Effect of ezetimibe on plasma cholesterol levels, cholesterol absorption, and secretion of biliary cholesterol in laboratory opossums with high and low responses to dietary cholesterol. Metabolism 2008, 57:1645-1654.
19. Lakoski S.G., Xu F., Vega G.L., et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. JClin Endocrinol Metab 2010, 95:800-809.
20. Gouni-Berthold I., Berthold H.K., Gylling H., et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008, 198:198-207.